Children's preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations.

ABSTRACT:

Background

Moxifloxacin (MFX) and linezolid (LZD) are key components of rifampicin-resistant TB treatment regimens. Currently, available dispersible tablet formulations of both drugs have poor palatability in children. We evaluated children's preferences for more child-friendly formulations from two generic manufacturers.

Methods

This was a randomised, cross-sectional 'swish-and-spit' taste panel study at two sites in South Africa. Each manufacturer created three flavour-blend variants for each drug. Healthy child volunteers 5-17 years old were sampled stratified by age, sex, and ethnic group and completed a preference rank-ordering and five acceptability 5-point Likert scales. We explored the blends' acceptability using summary, comparative, and ranking statistics.

Resul

SUBMITTER: Hoddinott G 

PROVIDER: S-EPMC11984522 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature